X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Debio 4126 (octreotide) is a synthetic octapeptide that mimics the pharmacology of endogenous somatostatin (SST). It demonstrates activity against growth hormone and glucagon, treating the disordered tissue growth and insulin regulation in patients with acromegaly.
Lead Product(s): Octreotide Acetate,Lanreotide Acetate
Therapeutic Area: Endocrinology Product Name: Debio 4126
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
Ipsen’s extensive experience with Somatuline Autogel / Somatuline Depot has offered deep insights into the challenges of living with gastroenteropancreatic neuroendocrine tumors, carcinoid syndrome or acromegaly.
Lead Product(s): Lanreotide Acetate
Therapeutic Area: Oncology Product Name: Somatuline Autogel
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Phillips - Medisize
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 16, 2022
Details:
New data presented at ENETS 2022 showed patients treated with Somatuline Autogel and Somatuline Depot (lanreotide) pre-filled syringe reported less frequent injection-site pain lasting more than two days than those treated with octreotide long-acting release syringe.
Lead Product(s): Lanreotide Acetate
Therapeutic Area: Oncology Product Name: Somatuline Autogel
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Company received final approval for its Lanreotide acetate-Generic Injection, from USFDA for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors.
Lead Product(s): Lanreotide Acetate
Therapeutic Area: Endocrinology Product Name: Lanreotide Acetate-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2021
Details:
Increasing the dose frequency of lanreotidefrom monthly to bi-monthly achieved a progression-free survival of 8.3 months in patients with progressive midgut neuroendocrine tumors (NETs) and 5.6 months in patients with progressive pancreatic NETs.
Lead Product(s): Lanreotide Acetate
Therapeutic Area: Oncology Product Name: Somatuline
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
